NYSE:NVS Novartis (NVS) Stock Price, News & Analysis $113.76 -0.10 (-0.09%) (As of 10/8/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Novartis Stock (NYSE:NVS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Novartis alerts:Sign Up Key Stats Today's Range$113.55▼$114.1950-Day Range$109.85▼$120.8952-Week Range$92.19▼$120.92Volume697,183 shsAverage Volume1.36 million shsMarket Capitalization$232.53 billionP/E Ratio15.35Dividend Yield2.14%Price Target$120.70Consensus RatingReduce Company OverviewNovartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.Read More… [SHOCKING] Crypto Document Leak… (Ad)The crypto market waits for no one. And my team of experts and I believe that a BIG move is right around the corner. That's why we're offering you instant access to the game-changing book that's transforming average investors into massive crypto successes.Download your digital copy now Novartis Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks51st Percentile Overall ScoreNVS MarketRank™: Novartis scored higher than 51% of companies evaluated by MarketBeat, and ranked 539th out of 994 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.9 / 5Analyst RatingReduce Consensus RatingNovartis has received a consensus rating of Reduce. The company's average rating score is 1.88, and is based on no buy ratings, 7 hold ratings, and 1 sell rating.Amount of Analyst CoverageNovartis has only been the subject of 4 research reports in the past 90 days.Read more about Novartis' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth9.47% Earnings GrowthEarnings for Novartis are expected to grow by 9.47% in the coming year, from $7.50 to $8.21 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Novartis is 15.35, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 120.65.Price to Earnings Ratio vs. SectorThe P/E ratio of Novartis is 15.35, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 118.32.Price to Earnings Growth RatioNovartis has a PEG Ratio of 1.71. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioNovartis has a P/B Ratio of 4.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Novartis' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.27% of the float of Novartis has been sold short.Short Interest Ratio / Days to CoverNovartis has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Novartis has recently decreased by 6.67%, indicating that investor sentiment is improving significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldNovartis pays a meaningful dividend of 2.12%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthNovartis does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Novartis is 32.79%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Novartis will have a dividend payout ratio of 29.60% next year. This indicates that Novartis will be able to sustain or increase its dividend.Read more about Novartis' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.27% of the float of Novartis has been sold short.Short Interest Ratio / Days to CoverNovartis has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Novartis has recently decreased by 6.67%, indicating that investor sentiment is improving significantly. News and Social Media3.7 / 5News Sentiment0.67 News SentimentNovartis has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Novartis this week, compared to 10 articles on an average week.Search Interest11 people have searched for NVS on MarketBeat in the last 30 days. This is an increase of 57% compared to the previous 30 days.MarketBeat Follows11 people have added Novartis to their MarketBeat watchlist in the last 30 days. This is an increase of 175% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Novartis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.01% of the stock of Novartis is held by insiders.Percentage Held by InstitutionsOnly 13.12% of the stock of Novartis is held by institutions.Read more about Novartis' insider trading history. Receive NVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter. Email Address NVS Stock News HeadlinesBrokerages Set Novartis AG (NYSE:NVS) Target Price at $120.70October 7 at 1:13 AM | americanbankingnews.comNovartis AG (NVS): Driving Long-Term Growth with Strong Pipeline and Innovative ProductsOctober 5 at 9:56 PM | msn.com[SHOCKING] Crypto Document Leak…The crypto market waits for no one. And my team of experts and I believe that a BIG move is right around the corner. That's why we're offering you instant access to the game-changing book that's transforming average investors into massive crypto successes.October 8, 2024 | Crypto 101 Media (Ad)Q3 2026 EPS Estimates for Novartis AG (NYSE:NVS) Cut by Zacks ResearchOctober 4, 2024 | americanbankingnews.comQ1 2025 Earnings Forecast for Novartis AG (NYSE:NVS) Issued By Zacks ResearchOctober 3, 2024 | americanbankingnews.comUS HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be NextOctober 1, 2024 | benzinga.comTeva launches first U.S. generic against Novartis antidiarrheal Sandostatin LAROctober 1, 2024 | msn.comNovartis: Value Continues To Build With Double-Digit Percentage Growth ProductsSeptember 30, 2024 | seekingalpha.comSee More Headlines NVS Stock Analysis - Frequently Asked Questions How have NVS shares performed this year? Novartis' stock was trading at $100.97 at the beginning of the year. Since then, NVS shares have increased by 12.7% and is now trading at $113.76. View the best growth stocks for 2024 here. How were Novartis' earnings last quarter? Novartis AG (NYSE:NVS) issued its earnings results on Thursday, July, 18th. The company reported $1.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.10. The company earned $12.87 billion during the quarter, compared to the consensus estimate of $12.24 billion. Novartis had a trailing twelve-month return on equity of 34.56% and a net margin of 33.76%. Does Novartis have any subsidiaries? The following companies are subsidiaries of Novartis: Gyroscope Therapeutics, Arctos Medical, Cellerys, Cadent Therapeutics, Vedere Bio, Vedere Bio ll, Amblyotech, and others. Who are Novartis' major shareholders? Top institutional investors of Novartis include Eldred Rock Partners LLC, Chesley Taft & Associates LLC, Park Avenue Securities LLC and Tealwood Asset Management Inc.. How do I buy shares of Novartis? Shares of NVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Novartis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), AT&T (T), Walt Disney (DIS) and Gilead Sciences (GILD). Company Calendar Last Earnings7/18/2024Today10/08/2024Next Earnings (Confirmed)10/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:NVS CUSIPN/A CIK1114448 Webwww.novartis.com Phone(161) 324-1111Fax41-61-324-7826Employees76,057Year Founded1996Price Target and Rating Average Stock Price Target$120.70 High Stock Price Target$130.00 Low Stock Price Target$114.00 Potential Upside/Downside+6.1%Consensus RatingReduce Rating Score (0-4)1.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$7.41 Trailing P/E Ratio15.36 Forward P/E Ratio15.17 P/E Growth1.71Net Income$14.85 billion Net Margins33.76% Pretax Margin22.75% Return on Equity34.56% Return on Assets14.24% Debt Debt-to-Equity Ratio0.47 Current Ratio0.93 Quick Ratio0.72 Sales & Book Value Annual Sales$45.44 billion Price / Sales5.12 Cash Flow$11.05 per share Price / Cash Flow10.30 Book Value$22.87 per share Price / Book4.98Miscellaneous Outstanding Shares2,044,000,000Free Float2,043,796,000Market Cap$232.59 billion OptionableOptionable Beta0.57 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report This page (NYSE:NVS) was last updated on 10/8/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novartis AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Novartis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
